Storia in 6 fonti

FDA approves Tregzi as first Treg cell therapy for allogenic transplant in blood cancers

The FDA has approved an allogeneic regulatory T cell immunotherapy for use in matched-donor hematopoietic stem cell transplantation in patients with blood cancers, to improve survival for chronic graft-versus-host disease.According to the manufacturer, this newly approved therapy (Tregzi, Orca Bio) is a “personalized treatment manufactured for each individual patient using living cells from

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo1 mese fa

FDA approves Tregzi as first Treg cell therapy for allogenic transplant in blood cancers

originale

FDA approves Tregzi as first Treg cell therapy for allogenic transplant in blood cancers

Confronto fonti

FDA approves Tregzi as first Treg cell therapy for allogenic transplant in blood cancers

Timeline cronologica

Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with…

FDA approves Tregzi as first Treg cell therapy for allogenic transplant in blood cancers

Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for…

Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers

Orca Bio makes a splash with FDA approval for cell therapy Tregzi. Could an IPO come next?

FDA approves Orca Bio’s cell therapy to improve transplant outcomes

FDA approves Orca Bio’s T cell therapy for blood cancer patients

Orca Bio makes a splash with FDA approval for cell therapy Tregzi. Could an IPO come next?

FDA approves Orca Bio’s T cell therapy for blood cancer patients

Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers

FDA approves Orca Bio’s cell therapy to improve transplant outcomes